Variable | Categorisation | Tumour-related death (OS) | Tumour recurrence (RFS) | ||||
---|---|---|---|---|---|---|---|
n | events | pc | n | events | pc | ||
Clinicopathological data: | |||||||
Tumour stagea | |||||||
pT1 | 46 | 7 | <0.0001 | 44 | 8 | <0.0001 | |
pT2 | 74 | 27 | 71 | 32 | |||
pT3 | 12 | 3 | 11 | 4 | |||
pT4 | 24 | 16 | 21 | 13 | |||
Lymph node statusa | |||||||
pN0 | 68 | 9 | <0.0001 | 66 | 13 | <0.0001 | |
pN1-3 | 83 | 40 | 79 | 42 | |||
Histological grade | |||||||
G1 | 16 | 4 | 0.005 | 15 | 5 | <0.0001 | |
G2 | 67 | 16 | 62 | 15 | |||
G3 | 72 | 33 | 70 | 37 | |||
Multifocality | |||||||
unifocal tumour | 130 | 43 | 0.545 | 123 | 47 | 0.689 | |
multifocal tumour | 26 | 10 | 24 | 10 | |||
Histological type | |||||||
ductal | 130 | 44 | 0.787 | 126 | 52 | 0.432 | |
lobular | 11 | 5 | 9 | 2 | |||
other | 13 | 4 | 11 | 3 | |||
Immunohistochemistry (IHC): | |||||||
Oestrogen receptor status | |||||||
negative (IRS 0–2) | 41 | 17 | 0.094 | 41 | 21 | 0.034 | |
positive (IRS 3–12) | 89 | 26 | 84 | 26 | |||
Progesterone receptor status | |||||||
negative (IRS 0–2) | 95 | 43 | <0.0001 | 88 | 43 | 0.001 | |
positive (IRS 3–12) | 41 | 5 | 41 | 6 | |||
HER2 IHC | |||||||
weak (0–2+) | 109 | 32 | 0.006 | 101 | 37 | 0.128 | |
strong (3+) | 25 | 14 | 25 | 12 | |||
RAI-3b | |||||||
low (IRS 0–4) | 78 | 25 | 0.816 | 76 | 29 | 0.897 | |
abundant (IRS 5–12) | 78 | 28 | 71 | 28 |